The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | Biomarkers predicting treatment benefit in BRAF-mutated NSCLC
Alessandro Di Federico, MD, Dana-Farber Cancer Institute, Boston, MA, identifies key biomarkers predicting treatment benefit in BRAF-mutated lung cancer patients, as seen in the FRONT-BRAF study. Tobacco use history and PD-L1 expression (≥1%) drive survival advantages with immunotherapy, confirmed through statistical adjustments including propensity score matching. TP53 co-mutation emerges as another crucial biomarker, where patients with both BRAF and TP53 mutations show significantly longer overall survival with immunotherapy, while TP53 wild-type patients benefit more from targeted therapy with longer progression-free survival. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
